Replimune Group Inc (REPL)
6.46
+0.11
(+1.73%)
USD |
NASDAQ |
May 01, 16:00
6.45
-0.01
(-0.15%)
After-Hours: 20:00
Replimune Group Cash from Financing (TTM): 16.34M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 16.34M |
September 30, 2023 | 272.90M |
June 30, 2023 | 279.89M |
March 31, 2023 | 311.30M |
December 31, 2022 | 311.74M |
September 30, 2022 | 44.27M |
June 30, 2022 | 38.00M |
March 31, 2022 | 6.598M |
December 31, 2021 | 7.024M |
September 30, 2021 | 265.25M |
June 30, 2021 | 264.07M |
March 31, 2021 | 372.46M |
Date | Value |
---|---|
December 31, 2020 | 371.71M |
September 30, 2020 | 199.88M |
June 30, 2020 | 209.66M |
March 31, 2020 | 100.17M |
December 31, 2019 | 100.17M |
September 30, 2019 | 9.962M |
June 30, 2019 | 101.60M |
March 31, 2019 | 101.39M |
December 31, 2018 | 101.35M |
September 30, 2018 | 101.20M |
June 30, 2018 | 54.56M |
March 31, 2018 | 54.75M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
6.598M
Minimum
Mar 2022
372.46M
Maximum
Mar 2021
172.79M
Average
199.88M
Median
Sep 2020
Cash from Financing (TTM) Benchmarks
Esperion Therapeutics Inc | 50.46M |
Gossamer Bio Inc | 190.15M |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |